Qualcomm (QCOM) stock slips as Mizuho flags Apple modem risk; what to watch next

Qualcomm (QCOM) stock slips as Mizuho flags Apple modem risk; what to watch next

New York, Jan 13, 2026, 12:19 (EST) — Regular session

  • Qualcomm shares dropped roughly 1.5% in midday trading, underperforming the wider chip sector rally.
  • Mizuho’s downgrade, pointing to handset “headwinds” and Apple modem exposure, continues to weigh on the stock.
  • Traders are eyeing Qualcomm’s Feb. 4 earnings call to get a clearer picture of demand and customer mix for 2026.

Qualcomm shares slipped roughly 1.5% to $166.80 on Tuesday, lagging behind the broader semiconductor sector as chip-focused ETFs edged up.

The broader market held steady following new U.S. inflation figures, with the S&P 500 tracker nearly flat and the Nasdaq-100 fund ticking up slightly. The Labor Department reported that consumer prices in December increased 2.7% year-over-year, while core inflation, excluding food and energy, came in at 2.6%. (Bureau of Labor Statistics)

For Qualcomm, interest rates matter — but handset demand matters more. Investors are grappling with how much pricing power and volume the company can maintain in 2026, as major customers tighten supply chains and consumers delay upgrades.

The pressure ramped up after Mizuho analyst Vijay Rakesh downgraded Qualcomm to Hold from Buy, cutting his price target to $175 from $200. He cited “handset headwinds” and weaker iPhone-related content as key concerns. “For QCOM, we believe the lower exposure to market leader Apple remains a key headwind for 2026E and beyond,” Rakesh said, also trimming his revenue and EPS forecasts. (TipRanks)

The warning tapped into a persistent concern: Apple’s push to handle more modem production internally, potentially cutting into Qualcomm’s chip sales for upcoming iPhones. Qualcomm has flagged to investors that this Apple shift might dampen growth, even if smartphone demand steadies. (Reuters)

Qualcomm is stepping up its efforts beyond smartphones, targeting the automotive sector. Earlier this month, Volkswagen announced plans for a long-term supply agreement to incorporate Qualcomm’s system-on-chips — which integrate several computing tasks — into infotainment systems on a new software platform set to launch in 2027. (Reuters)

On the supply front, Qualcomm’s CEO Cristiano Amon revealed the company is in discussions with Samsung Electronics over contract manufacturing with a 2-nanometre process. This “foundry” deal would have Qualcomm outsourcing chip production to Samsung. (Reuters)

The wider chip sector held steady Tuesday. Intel and AMD surged following KeyBanc’s upgrades, sparking a risk-on vibe in parts of the industry that Qualcomm didn’t catch. (Barron’s)

Qualcomm’s downside risk remains clear: weaker handset sales, a faster-than-anticipated drop in Apple-related content, and diversification failing to make up the shortfall in time. If pricing pressure emerges as a tool to protect market share, margins could take a serious hit.

Macro factors could still shake the sector in the short term. The upcoming U.S. producer-price report, set for Wednesday, will put rate expectations back under the microscope. (Bureau of Labor Statistics)

Qualcomm’s upcoming key event is its fiscal first-quarter earnings call on Feb. 4. Investors will focus on any updates about handset demand, insights into Apple modem schedules, and whether growth in automotive and IoT sectors is gaining enough traction to support the stock. (Qualcomm)

Stock Market Today

  • ABBV inks drug pricing deal with Trump, joins PD-1xVEGF bandwagon
    January 13, 2026, 2:32 PM EST. AbbVie said it signed a U.S. pricing agreement with the Trump administration to cut list prices to match those in comparable developed markets, backing the MFN proposal. The deal includes a three-year exemption from import tariffs on pharmaceutical ingredients if AbbVie expands U.S. manufacturing, and a pledge to invest $100 billion over the next decade in domestic R&D and capital. The government says 16 of 17 large drugmakers have reached similar accords; Regeneron remains in talks. In a separate release, AbbVie agreed to an exclusive license with RemeGen for its PD-1xVEGF bispecific, RC148. AbbVie will pay an upfront $650 million and up to $4.95 billion in milestones, plus royalties, for rights outside Greater China. RC148 is in phase II in China, with potential in NSCLC and CRC. Competitors include Summit, BioNTech/Bristol Myers, Merck and Pfizer pursuing PD-1/VEGF programs.
TransMedics stock jumps as SEC filing details $23.9 million-a-year lease for new Massachusetts HQ
Previous Story

TransMedics stock jumps as SEC filing details $23.9 million-a-year lease for new Massachusetts HQ

Lam Research stock stalls near highs as BofA lifts target to $245, more boosts follow
Next Story

Lam Research stock stalls near highs as BofA lifts target to $245, more boosts follow

Go toTop